Analysis Of Income And Expense [Abstract]

Zealand Pharma - Filing #5889383

Concept	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue	—	62,691,000 DKK	—	—	—	—	342,788,000 DKK	—	—	—
Material income and expense [abstract]
Royalty expense	—	- DKK	—	—	—	—	9,138,000 DKK	—	—	—
Research and development expense	—	919,866,000 DKK	—	—	—	—	684,902,000 DKK	—	—	—
Selling, general and administrative expense [abstract]
General and administrative expense	—	315,907,000 DKK	—	—	—	—	185,302,000 DKK	—	—	—
Operating expense excluding cost of sales	—	1,327,024,000 DKK	—	—	—	—	895,852,000 DKK	—	—	—
Sales and marketing expense	—	88,115,000 DKK	—	—	—	—	30,627,000 DKK	—	—	—
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	- DKK	316,000 DKK	- DKK	316,000 DKK	- DKK	- DKK	8,087,000 DKK	- DKK	- DKK	8,087,000 DKK
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	- DKK	1,079,144,000 DKK	- DKK	316,000 DKK	1,078,828,000 DKK	- DKK	695,652,000 DKK	703,739,000 DKK	- DKK	8,087,000 DKK